Tennessee Headlines

“Lewy Body Dementia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lewy Body Dementia Market.

The Lewy Body Dementia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Lewy Body Dementia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Lewy Body Dementia treatment therapies with a considerable amount of success over the years. 

• Lewy Body Dementia companies working in the treatment market are Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc, and others, are developing therapies for the Lewy Body Dementia treatment 

• Emerging Lewy Body Dementia therapies in the different phases of clinical trials are- E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others are expected to have a significant impact on the Lewy Body Dementia market in the coming years.  

• In April 2024, Cognition Therapeutics, a US-based biopharmaceutical firm, has completed subject enrollment for its Phase II SHIMMER study of CT1812, aimed at treating mild-to-moderate dementia with Lewy bodies (DLB). This study assesses the safety and efficacy of CT1812, a novel treatment for adults with DLB. The double-blind, placebo-controlled trial has enrolled 120 adults with mild-to-moderate DLB, who will receive either a placebo or one of two oral doses of CT1812 over six months.

• In February 2024, CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company dedicated to developing therapies for degenerative brain diseases, announced that data from the AscenD-LB Phase 2a trial on neflamapimod treatment in patients with dementia with Lewy bodies (DLB) have been published online in the Journal of Prevention of Alzheimer’s Disease (JPAD).

• In August 2023, EIP Pharma, a US-based biopharmaceutical company, has administered the first dose in its RewinD-LB clinical trial, investigating neflamapimod for treating dementia with Lewy bodies (DLB). This Phase IIb trial (NCT05869669) of the pipeline drug neflamapimod (VX-745) follows encouraging results from the earlier Phase IIa AscenD-LB trial.

Lewy Body Dementia Overview

Lewy Body Dementia (LBD) is a progressive brain disorder characterized by abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, known as Lewy bodies, affect chemicals in the brain and can lead to problems with thinking, movement, behavior, and mood. LBD encompasses two related conditions: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).

Get a Free Sample PDF Report to know more about Lewy Body Dementia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/lewy-body-dementia-lbd-pipeline-insight

Emerging Lewy Body Dementia Drugs Under Different Phases of Clinical Development Include:

• E2027: Eisai

• Neflamapimod: EIP Pharma

• K0706: Sun Pharma

• RVT-101: Axovant Sciences Ltd.

• CT1812: Cognition Therapeutics

• K0706: Cephalon

• Irsenontrine: Eisai Inc.

• Neflamapimod: EIP Pharma Inc

• Donepezil: Eisai Co., Ltd.

• ATH-1017: Athira Pharma

• Galantamine: Ortho-McNeil Neurologics, Inc.

• Memantine: H. Lundbeck A/S

• Nelotanserin: Axovant Sciences Ltd.

• DatSCAN: GE Healthcare

• NYX-458: Aptinyx

• N-831(Traneurocin): NeuroActiva, Inc.

• CST-103, CST-107: CuraSen Therapeutics, Inc.

• Pimavanserin: ACADIA Pharmaceuticals Inc.

Lewy Body Dementia Pipeline Therapeutics Assessment

• Lewy Body Dementia Assessment by Product Type

• Lewy Body Dementia By Stage and Product Type

• Lewy Body Dementia Assessment by Route of Administration

• Lewy Body Dementia By Stage and Route of Administration

• Lewy Body Dementia Assessment by Molecule Type

• Lewy Body Dementia by Stage and Molecule Type

DelveInsight’s Lewy Body Dementia Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Lewy Body Dementia product details are provided in the report. Download the Lewy Body Dementia pipeline report to learn more about the emerging Lewy Body Dementia therapies

Some of the key companies in the Lewy Body Dementia Therapeutics Market include:

Key companies developing therapies for Lewy Body Dementia are – Jazz Pharmaceuticals Inc., Allergan Plc., Noven Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, BioArctic AB, Sumitomo Pharma Co. Ltd., Novartis AG, GSK Plc., and others.

Lewy Body Dementia Pipeline Analysis:

The Lewy Body Dementia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Lewy Body Dementia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lewy Body Dementia Treatment.

• Lewy Body Dementia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Lewy Body Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lewy Body Dementia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Lewy Body Dementia drugs and therapies

Lewy Body Dementia Pipeline Market Strengths

• Increasing research and development to understand the diversity of the disease might improve the diagnosis of LBD thereby resulting in a lucrative market opportunity.

• Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Lewy Body Dementia Pipeline Market Opportunities

• Several organizations are actively working to provide information and increase awareness of such disorders.

• There is only one approved treatment option for LBD which opens a platform of new therapies to boost the market ofLBD.

• The pipeline for PMM is narrow as there is limited R&D activity

Scope of Lewy Body Dementia Pipeline Drug Insight    

• Coverage: Global

• Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc, and others

• Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others

• Lewy Body Dementia Therapeutic Assessment: Lewy Body Dementia current marketed and Lewy Body Dementia emerging therapies

• Lewy Body Dementia Market Dynamics: Lewy Body Dementia market drivers and Lewy Body Dementia market barriers 

Request for Sample PDF Report for Lewy Body Dementia Pipeline Assessment and clinical trials

Table of Contents

1. Lewy Body Dementia Report Introduction

2. Lewy Body Dementia Executive Summary

3. Lewy Body Dementia Overview

4. Lewy Body Dementia- Analytical Perspective In-depth Commercial Assessment

5. Lewy Body Dementia Pipeline Therapeutics

6. Lewy Body Dementia Late Stage Products (Phase II/III)

7. Lewy Body Dementia Mid Stage Products (Phase II)

8. Lewy Body Dementia Early Stage Products (Phase I)

9. Lewy Body Dementia Preclinical Stage Products

10. Lewy Body Dementia Therapeutics Assessment

11. Lewy Body Dementia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Lewy Body Dementia Key Companies

14. Lewy Body Dementia Key Products

15. Lewy Body Dementia Unmet Needs

16 . Lewy Body Dementia Market Drivers and Barriers

17. Lewy Body Dementia Future Perspectives and Conclusion

18. Lewy Body Dementia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/